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A Bayesian Model for Age, Period, and Cohort Effects on
Mortality Trends for Lung Cancer, in Association with
Gender-Specific Incidence and Case–Fatality Rates
Chun-Ru Chien, MD, PhD,* and Tony Hsiu-Hsi Chen, PhD†
Introduction: To study time trends in lung cancer mortality by
separating the incidence and case–fatality rates, in association with
age, period, and cohort effects.
Methods: Lung cancer cases (n  44,139) diagnosed between 1996
and 2002 in Taiwan were analyzed by decomposing the time trend
in mortality into incidence and case–fatality rates. Descriptive data,
together with periodical treatment distribution (surgery, chemother-
apy, and others) were analyzed using a Bayesian age, period, and
cohort (BAPC) model.
Results: Midterm mortality (2-year age-adjusted standardized mor-
tality rate) has been decreasing for male lung cancer patients since
about 2000, mainly because of a decrease in incidence during this
period. For women, 2-year age-adjusted standardized mortality rate
has been slightly increasing, mainly as a result of increasing inci-
dence. There were small improvements (3–6%) in the short-term
(1-year) case–fatality rate, possibly owing to increased utilization
(15–18%) of chemotherapy. The midterm (2-year) case–fatality
rate remained roughly the same, especially for men.
Conclusions: Using a new BAPC model, we found that the trends
in mortality for lung cancer paralleled the changes in incidence, with
opposite effects in men and women. Increased utilization of chemo-
therapy might have partly accounted for the small improvement in
the case–fatality rate. The contributions of other unmeasured factors
such as staging and histologic distribution remain to be clarified in
future studies.
Key Words: Bayes Theorem, Lung Neoplasms, Treatment Utiliza-
tion, Trends.
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Although time trends in lung cancer incidence and mortal-ity have been studied previously,1–4 it is of interest to
study these in a country such as Taiwan, with a low but
rapidly increasing incidence rate for lung cancer. Lung cancer
is the leading cancer in Taiwan1,2,4,5 and accounts for 19.6%
of deaths from cancer, with the highest increase in mortality
for both men and women worldwide.1–3,5
The advent of new treatments may contribute to the time
trends in case–fatality rates, which in turn affect mortality.
Although trend analyses of cancer incidence and mortality
have been conducted based on cancer registry data, these
analyses did not include etiological factors, and few studies
have separated the time trend in case–fatality rates from that
in the incidence by using a classic age–period–cohort (APC)
analysis. The APC model is a Poisson regression model, in
which the number of events (incidence or death) is analyzed
according to age at each event (age), year of the event
(period), and year of birth (cohort). The age effect accounts
for the duration of the exposure to risk factors. The period
effect represents factors that have an impact on all individuals
at the same time, regardless of age. The cohort effect corre-
sponds to an exposure that is specific to each generation.6,7
In this study, we developed a Bayesian APC (BAPC)
effect model to study time trends in lung cancer incidence and
mortality in Taiwan. The case–fatality time trend was sepa-
rated from the time trend for incidence, to assess the influence
of the contemporaneous trends of treatment utilization and
treatment-specific mortality on the time trend in the case–
fatality rate.
MATERIALS AND METHODS
Data Sources
Information on all newly diagnosed cases of lung can-
cer in Taiwan between 1979 and 2002 (n  91,811) was
taken from the Cancer Registry of the Bureau of Health,
Department of Health, Taiwan. The median age at diagnosis
was 66 (SD  3.3) years. The male to female ratio was 2.44
(65,110/26,701). Lung cancer in this study was defined ac-
cording to ICD code 162. Information on death (all-cause
mortality) was obtained by linking these incident cases of
lung cancer with the national mortality registry until the end
of December 2004. The denominator of population size used
to calculate the number of person-years during the contem-
poraneous period was obtained from the Ministry of the
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Interior of Taiwan.8 The Cancer and Death Registries were
missing up to 20% of the data before 1985, but percentage
has been gradually reduced to 0.1% since 1996; therefore,
only data from 1996 to 2002 (n  44,139) were included in
the analysis of age at diagnosis between 20 and 89 years old.
The initial treatment was also recorded in the Cancer
Registry. The percentage of missing data decreased gradually
and was 5% after 1996. The treatments were classified as
surgery (with/without other treatment), chemotherapy (with-
out surgery, with/without other treatment), and other (modi-
fied from Ref. 9), and treatment-specific 1- and 2-year case–
fatality rates were calculated. Staging information was not
available in the National Cancer Registry by the end of 2007
and was therefore not included in our analysis. Tumor grad-
ing was also not included, as its prognostic significance was
still elusive.10 Other clinical characteristics of these 44,139
patients are listed in Table 1.
Relationships Between Incidence,
Case–Fatality, and Mortality
The mortality rate in an underlying population is a
function of the incidence and case–fatality rate, and thus the
1- or 2-year mortality rate was approximately decomposed by
applying the following formula:
Mortality Rate
 Incidence Rate (incident cases/person-years)
 t-year Case–Fatality Rate
(number of deaths/number of incident cases),
where t-year is 1- or 2-year. Note that the rare disease
assumption was applied to the incidence and mortality rates.
Statistical Analysis
We divided the observed cases into seven 1-year peri-
ods, between 1996 and 2002. Given that lung cancer is
uncommon in younger populations and is not usually actively
treated in elderly patients, 70 age bands between 20 and 89
years and 76 cohorts (first cohort born in 1908, 76th cohort
born in 1983) were included in the model.
We used data from the seven periods to estimate crude
age- and gender-specific incidence rates, as well as the
age-adjusted standardized incidence rate (ASIR) and age-
adjusted standardized mortality rate (ASMR). The 1-year
mortality (death within 1 year after diagnosis) and 2-year
mortality (death within 2 years after diagnosis) were pre-
dicted for comparison with the corresponding observed rates.
The ASIR and ASMR were calculated using the 2002 popu-
lation as a reference. The case–fatality rate was calculated as
in the abovementioned formula.
We assumed that the number of incident cases or deaths
in each age/period group followed a Poisson distribution with
the rare disease assumption, which was appropriate in our
study because the highest incidence was 0.5% (31/5640). A
BAPC model with logarithm transformation was used to
model the expected number of outcomes, including incidence
and 1- and 2-year mortality, as a function of age, period, and
cohort effects. The model form was as follows:
Events(i)  Poisson ((i))
Log((i))  Log(person-year(i))  age(i)
 period(i)  cohort(i)  Interaction
Log (person-year) is often called offset. In addition to
age (), the effects of period and cohort ( and ) were
explicitly explained by the regression coefficients. For exam-
ple, in the incidence model for 45-year-old men diagnosed in
1998, the median period and cohort coefficients were 0.038
and 0.07041, respectively, reflecting the magnitudes of the
effects of the period 1998 and the cohort born in 1953. We
used the method proposed by Albert in 199611 for model
selection of the interaction terms between 2 of the 3 compo-
nents: age, period, and cohort effects. Although our model
can be adapted to study the interactions among age, period,
and cohort effects, we expected that the interaction between
the age and period effects would be more significant than
other interactions. Regarding the parameters for estimation,
for the model without interaction, there were 153 parameters
(70 for age, 7 for period, and 76 for cohort). For the final
model in our analysis (with an age–period interaction), an
additional 490 parameters (70  7) were added, for a total of
643 parameters. A Gaussian autoregressive prior model was
used to smooth the age, period, and cohort effects and to
extrapolate the period and cohort effects from their second
autoregressive order.
The program was implemented with WinBUGS soft-
ware (MRC Biostatistics Unit, Cambridge, UK) using
Markov Chain Monte Carlo methods. Posterior distributions,
from which we drew inferences on incidence/mortality and
case–fatality rates, were generated from 5000 iterations, after
discarding 500 burn-in iterations. We defined the median
iterative value as an overall summary and defined the 95%
credibility intervals (CI) using 2.5 and 97.5 percentiles of the
5000 iterated results. The program is available from the
authors (Chen or Chien) upon request.
RESULTS
Model Selection
Incidence was modeled as the outcome of interest for
men, and the model with an age–period interaction was
TABLE 1. Clinical Characteristics of the Study Population
(n  44,139) by Calendar Year
Variable by
Calendar Year 1996 1997 1998 1999 2000 2001 2002
Number of cases 5,180 5,471 6,094 6,626 6,897 6,853 7,018
Median age (years) 68 68 69 69 70 70 70
Gender (% male) 71 70 70 69 70 68 67
Histology
(% adenocarcinoma)
34 36 39 39 42 44 43
Surgery (%)a 16 17 17 17 18 19 17
Chemotherapy (%)a 20 22 29 29 35 35 38
Radiotherapy (%)a 32 31 26 23 26 26 26
a Percentage receiving surgery, chemotherapy, or radiotherapy as part of their initial
treatment.
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statistically more significant than that in the absence of this
interaction. Similarly, the age–period interaction was signif-
icant in the models of incidence and 1- and 2-year mortality
in women. Accordingly, our subsequent estimations were
based on models that included an age–period interaction.
Gender- and Age-Specific Rates
Figures 1–3 (A, men; B, women) show the observed (A)
and estimated (E) gender-specific curves for incidence
(ASIR) and 1- and 2-year mortality (ASMR), with the re-
spective 95% CI. In general, the estimated values were
close to the observed values, indicating the adequate fit of
the model.
For men, the ASIR and the 1- and 2-year ASMRs
showed a peak around the year 2000 and then gradually
declined. For women, the ASIR increased rapidly from 1996
to 1999, after which the rate increase slowed. The 1-year
ASMR was relatively steady during this same period, but the
2-year ASMR slowly increased.
Case–Fatality
Time trends for mortality may be influenced by those
for incidence or case–fatality rate, as mentioned in the meth-
ods section. The time trends for 1- and 2-year case–fatality
rates for men and women (Figure 4A, B) were studied to
identify the relative contributions of incidence and case–
fatality to mortality. For men, the 2-year case–fatality rate
was stable during this period and the 1-year case–fatality rate
fell by 3% between 1997 and 1998. This implies that the
improvement in male mortality after 2000 (Figures 2A and
3A) was attributable mainly to a reduction in incidence,
which contributed to the reduction in the case–fatality rate
(bottom of Figure 4A shows 1-year case–fatality rate). In
women, the 1-year case–fatality rate fell markedly by 6%
between 1997 and 1999, but this improvement was counter-
acted by a large increase in the incidence, resulting in an
increase in mortality, particularly 2-year ASMR.
Trends in Treatment Utilization and Related
Case–Fatality Rates
The time trends for treatment utilization in conjunction
with 1- and 2-year case–fatality rates by gender are displayed
in Figure 5A–C. The 1-year case–fatality rate improved for
both male and female patients who did not receive surgical
treatment, and the 2-year case–fatality rate remained steady
when chemotherapy was administered. For men, between
1996 and 2002, treatment utilization was stable for surgery
FIGURE 1. The age-adjusted stan-
dardized incidence rate (ASIR). A,
Actual; L and H, 2.5 and 97.5%
credibility interval; E, estimated;
Panel A, male; Panel B, female.
FIGURE 2. 1-year age-adjusted
standardized mortality (ASMR). A,
Actual; L and H, 2.5 and 97.5%
credibility interval; E, estimated;
Panel A, male; Panel B, female.
FIGURE 3. 2-year age-adjusted
standardized mortality (ASMR). A,
Actual; L and H, 2.5 and 97.5%
credibility interval; E, estimated;
Panel A, male; Panel B, female.
FIGURE 4. Estimated case–fatality
rate (with 95% credibility interval).
1 years, 1 year; 2 years, 2 year; L
and H, 2.5 and 97.5% credibility
interval; E, estimated; Panel A, male;
Panel B, female.
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(average, 17%) and increased for chemotherapy (19–34%)
compared with other treatments. The 1-year case–fatality rate
was lower for those treated with chemotherapy (average,
62%) than for those treated with other modalities (average,
77%). There was also moderate improvement in the surgery-
related 1-year case–fatality rate (39–33%) from 1996 to
2002. For women, between 1996 and 2002, treatment utili-
zation was also stable for surgery (average, 18%) and in-
creased for chemotherapy (15–33%) compared with other
modalities, and the corresponding 1-year case–fatality rate
was lower with chemotherapy (average, 51%) than with other
modalities (average, 72%). There was also slight improve-
ment in the surgery-related 1-year case–fatality rate (33–
25%) from 1996 to 2002. These data are compatible with the
improvement in the 1-year case–fatality rate and imply that
the improvement was mainly the result of increased utiliza-
tion of chemotherapy:
For men, (34 –19%)  (77– 62%)  2.25%;
For women, (33–15%)  (72–51%)  3.8%.
DISCUSSION
By using a BAPC model in conjunction with the de-
composition of mortality into incidence and case–fatality
rates, we demonstrated that in a country such as Taiwan with
low incidence of lung cancer, the time trend in mortality for
lung cancer was opposite in men and women. The midterm
mortality (2-year ASMR) for male lung cancer patients de-
creased after about 2000, mainly as a result of decreased
incidence (ASIR) during this period. In contrast, women
showed a moderate increase in midterm (2-year) mortality,
attributable primarily to increased incidence. Regarding
case–fatality rates, there was a small improvement in the
short-term (1-year) rate, which was possibly caused by in-
creased utilization of chemotherapy, but the improvement in
the midterm (2-year) case–fatality rate was still lacking,
especially for men.
Our results are compatible with those in the literature,
which have shown that most lung cancer patients are diag-
nosed at an advanced, incurable stage, given the currently
available treatment options. Although chemotherapy can lead
to modest gains in survival (e.g., 2–4 months in advanced
non-small cell lung cancer NSCLC), the long-term outcome
in lung cancer patients is still poor.12,13
In contrast to previous studies,2,3,14 our study included
some unique features. First, both incidence and mortality data
were simultaneously analyzed. It is well known that using
mortality data to make an inference has the drawback of not
separating the effects of the case–fatality rate from real
changes in the underlying incidence. The prognosis of lung
cancer is poor, and the mortality is therefore approximately
equal to the incidence rate. However, there have been major
advances in treatments such as chemotherapy over the past 5
years, and a high response rate to biologic therapy has been
demonstrated in Asian lung cancer patients.12,15 Accordingly,
it is better to use the incidence and mortality, rather than
either alone, to assess epidemiological long-term trends for
lung cancer.
Second, we used a Bayesian, rather than classic, APC
model 16 As in some previous studies,7,17 this approach
provided more reliable and stable estimations. We also
found that the estimations were highly accurate. Further-
more, the estimation of CI is not intractable, as has been
seen previously.2,3
There are several potential limitations in our study. The
first is that the study period (1996–2002) was not very long,
owing to the limited availability of information regarding
treatment and survival status. Therefore, we did not investi-
gate long-term mortality, as is usually assessed in other
cancers such as breast cancer. However, given that lung
cancer is a highly fatal disease with 5-year overall survival
rates of 15% and a 2-year survival rate of 10–15% for the
majority of patients with advanced NSCLC,13 we believe that
our description of the trends for midterm mortality (2 years)
may be sufficient for studying the time trend for lung cancer
in association with age, period, and cohort effects. In addi-
tion, as most of the randomized controlled studies supporting
the efficacy of chemotherapy versus best supportive care for
advanced NSCLC patients were published between 1988 and
1999,18 we consider our study period to be appropriate for
investigating the effect of chemotherapy. Nonetheless, more
recent cohorts and longer follow-up periods will be needed in
future studies, especially in view of recently published break-
through studies on the treatment of NSCLC.19–22
FIGURE 5. Trends of treatment utilization and related case–
fatality rate. 1 years, 1 year; 2 years, 2 year; M, male; F, fe-
male; op, operation; chemo, chemotherapy.
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The second limitation is that cancer staging information
was not available in our study. However, the trends in staging
distribution in Taiwan have indicated an increase in the
proportion of cancers at an advanced stage in the contempo-
raneous period,23 making the improved short-term case-fatal-
ity rate less likely to have been caused by an increase in
early-stage cancer diagnosis.
A third limitation is that we did not measure survival
according to histologic subtype (i.e., adenocarcinoma versus
nonadenocarcinoma). In Taiwan, as in Western countries, the
number of adenocarcinoma patients, who are supposed to
have relatively good survival, has increased,24 and this may
partly account for the improved short-term case–fatality rate.
However, this is unlikely to have made a substantial contri-
bution to the improved short-term fatality rate. The crude
1-year case–fatality rate was slightly better for adenocarci-
noma patients (62% for men and 55% for women) than for
nonadenocarcinoma patients (67% for men and 63% for
women), and between 1996 and 2002, the proportion of
adenocarcinoma patients has increased from 28 to 35% of
men and from 47 to 61% of women. Therefore, the absolute
contribution of the increased percentage of adenocarcinoma
patients to the improvement in the 1-year case–fatality rate
would have been 0.4% for men and 1.1% for women, which
constitutes only a small part of our observed improvement
(3% for men and 6% for women). However, it is still unclear
whether the cell type is a prognostic factor in NSCLC.10
In this study, we developed a Bayesian APC model to
study time trends in lung cancer incidence and mortality in
Taiwan, which has a low but rapidly increasing incidence of
lung cancer. By applying this new BAPC model to time trend
data from Taiwan and by decomposing mortality into the
incidence and case-fatality rates, we demonstrated that mid-
term (2-year) mortality has been decreasing for male lung
cancer patients since about the year 2000, whereas the oppo-
site is true for female patients and that the change in mortality
during this period paralleled the change in incidence, which
was opposite in men and women. Increased utilization of
chemotherapy might have partly accounted for the small
(3–6%) improvement in the short-term (1-year) case–fatality
rate. The contributions of other unmeasured factors such as
staging and histologic distribution remain to be clarified in a
future study.
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